GNF-7

• Description :

  GNF-7 is a multikinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC50s of 133 nM and 61 nM for Bcr-AblWT and Bcr-AblT315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC50s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  Ack1; Bcr-Abl

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/GNF-7.html

• Purity :

  99.70

• Solubility :

  DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(NC1=CC=C(C)C(N2CC3=CN=C(NC4=CC=C(C)N=C4)N=C3N(C)C2=O)=C1)C5=CC=CC(C(F)(F)F)=C5

• Molecular Formula :

  C28H24F3N7O2

• Molecular Weight :

  547.53

• Precautions :

  H301

• References & Citations :

  [1]Choi HG, et al. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J Med Chem. 2010 Aug 12;53 (15) :5439-48.|[2]Lu X, et al. Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl (T315I) mutant. Bioorg Med Chem Lett. 2015 Sep 1;25 (17) :3458-63.|[3]Cho, H., et al. First SAR study for overriding NRAS mutant driven acute myeloid leukemia. Journal of Medicinal Chemistry.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [839706-07-9]